🌞 What a lovely day for pitches and networking! 💊 After the rains had gone, Life Science Pitch Day kicked off! IZB - Innovation and Start-up Center Biotechnology, Boehringer Ingelheim Venture Fund, Leaps by Bayer, MEDICE - The Health Family and HTGF | High-Tech Gründerfonds once again brought together Life Science founders, investors in the life sciences and healthcare sector as well as representatives of the industry. 10 startups presented their pitches to more than 40 investors and industry experts: First to present was TECregen AG: Georg Hollander introduced this Immuno-Rejuvenation start-up and its vision to develop transformative, next-generation, synthetic ligands to regenerate the thymus. Then, Carlo Bertozzi, pitched for InCephalo and their approach to developing next-generation brain-cancer therapies. Torsten Mummenbrauer presented PreVacta: an integrated vaccine and therapeutics company, combining unique expertise in synthetic (glyco-)chemistry, immunology and clinical infectious diseases. Kupando GmbH makes use of the oldest mechanism of defense, as presented by Johanna Holldack: TLRs operate to detect signature molecules that herald infection and cancer by activating the innate immune system. Lukas Linning presented Akribion Genomics / Therapeutics and their new modality of guided cancer-cell killing, targeting cancer-specific RNA biomarker expression using easily programmable cytotoxic nucleases with high specificity for a wide range of RNA targets. Niels von Wardenburg pitched Teneura and its mission to cure neurological autoimmune diseases using engineered T-cell therapies. Dr. Arthur Dopler presented QUASAR THERAPEUTICS and their innovative regulators of the complement system to address rare but life-threatening diseases and to solve the problems of current inhibitors in the clinic. Dr. Teresa Wagner pitched for immuneAdvice and their visualization of immune cells to guide immunotherapy. Frank Pressler introduced Citrapeutics: First on target, first in class ACOD1 inhibitors to boost anti-tumor immunity and inhibit cancer cell proliferation for: Triple negative breast cancer, non-ICI responsive melanoma, Head and neck and Colon cancer. Finally, Christin Zuendorf presented TQ Therapeutics. This start-up is developing a novel manufacturing platform for cell therapeutics, that will enable the production of cellular drugs with an integrated, highly automated extracorporeal gene therapy approach. Our keynote speaker, Daniel Vitt, CEO of Immunic Therapeutics will close the day - which we'll now be rounding out with some networking. Thank you to Christian Gnam, Marion Köhler and the whole IZB Team for the logistics and the unique venue. Thank you also to Karin Hofelich for joining us! CC: Angelika Vlachou, Bernd Goergen, Niels Sharman, Katharina Severin, Laura Pedroza
-
+1